Avails Medical

Executive Summary

Avails Medical is a US-based diagnostics company addressing the critical challenge of antimicrobial resistance (AMR) through its innovative rapid antimicrobial susceptibility testing (AST) platform. The company's FDA-cleared eQUANT™ System leverages proprietary electronic biosensor technology to deliver pathogen identification and susceptibility results directly from patient samples in hours, rather than days. This speed enables clinicians to make informed treatment decisions earlier, significantly improving outcomes for infectious disease patients, particularly those with sepsis. By reducing reliance on broad-spectrum antibiotics, Avails Medical's solution supports antimicrobial stewardship and helps combat the growing threat of drug-resistant infections. Currently, Avails Medical is focused on commercializing the eQUANT System in the U.S. hospital market, targeting microbiology laboratories and critical care settings. The company's technology addresses a large unmet need, with the global AST market expected to exceed $5 billion by 2030. Early adoption and strategic partnerships with hospital systems and reference labs are key to scaling its footprint. As a private entity with a cleared product and a clear value proposition, Avails Medical is well-positioned to capture market share and drive adoption, with potential for expansion into additional indications and geographic markets.

Upcoming Catalysts (preview)

• Q3 2026First commercial hospital installations of eQUANT System70% success
• Q4 2026Announcement of strategic partnership with major hospital network or diagnostic distributor60% success
• Q1 2027Series C funding round to support commercial scale-up80% success